{
  "docId": "019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "docSlug": "8c206fa848e149a61a796c5e8f53c9e1",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 37,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The chart displays efficacy data for a drug candidate, noting the impact of anti-drug antibodies (ADAs) on the third cohort.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a7a3-7510-9ab9-5e74cd7e6c44/11",
  "deckHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "deckJsonHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44.json",
  "deckAnchorHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.06,
        "y": 0.215
      },
      "kind": "chart",
      "text": "Percent Change of Homocysteine from Baseline After 4 Once-Weekly Treatments",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa6bf4be-46cb-4ed7-b6b9-efd3fe700bf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.68,
        "y": 0.3
      },
      "kind": "list",
      "text": "Data from Cohorts 1 and 2 showed that treatment with pegtarviliase lowered total homocysteine levels when compared to baseline values. Cohort 3 data confounded by presence of anti-drug antibodies (ADAs). Potential to dose through ADAs with longer treatment duration and/or higher dose",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1017179c-f158-42e3-ba79-0098a4785734",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.06,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "*n=3 for 7 days post dose, due to missing data point from one of four evaluable patients",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7925ecd-bba8-4bee-8408-b35718ffc007",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.75,
        "x": 0.06,
        "y": 0.08
      },
      "kind": "title",
      "text": "Interim Results from Phase 1/2 Clinical Trial: Lowering of Homocysteine",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b73c571-ac34-42de-a7ee-3c348461636d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 9,
      "beatId": "7c8dedf5-5b20-4ddd-bab4-25563ee26ac5",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Pegtarviliase as a solution to lower homocysteine levels",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 12,
      "from": 11,
      "beatId": "53315100-e2a8-4809-bf83-d6e3abc2c164",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence and Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents interim results from the Phase 1/2 clinical trial",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}